In support to this, in vitro and in vivo silencing of FBXW7 in non-small cell lung cancer (NSCLC) can significantly trigger EMT, promote migration and invasion and confer resistance to gefitinib treatment [151]. Here, FBXW7 is linked to non-small cell lung carcinoma.